PDF(Pubmed)
Abstract：
UNASSIGNED: In China, grade 2 to 3 immune-related rash will probably lead to the interruption of immunotherapy. Corticosteroid (CS) is the main treatment, but not always effective. The external application of clearing heat and removing dampness, which is represented by Qing-Re-Li-Shi Formula (QRLSF), has been used in our hospital to treat immune-related cutaneous adverse events (ircAEs) for the last 5 years. The purpose of this study was to discuss its efficacy and safety in the treatment of grade 2 to 3 rash.
UNASSIGNED: A retrospective study of patients with grade 2 to 3 immune-related rash in our hospital from December 2019 to December 2022 was conducted. These patients received QRLSF treatment. Clinical characteristics, treatment outcome, and health-related quality of life (HrQoL) were analyzed.
UNASSIGNED: Thirty patients with grade 2 to 3 rash (median onset time: 64.5 days) were included. The skin lesions of 24 cases (80%) returned to grade 1 with a median time of 8 days. The accompanying symptoms were also improved with median time of 3 to 4 days. The addition of antihistamine (AH) drug didn\'t increase the efficacy of QRLSF (AH + QRLSF: 75.00% vs QRLSF: 83.33%, P = .66). No significant difference was observed in the efficacy of QRLSF treatment regardless of whether patients had previously received CS therapy (untreated population: 88.24% vs treated population: 69.23%, P = .36). During 1-month follow-up, 2 cases (8.33%) underwent relapses. In terms of HrQoL, QRLSF treatment could significantly reduce the median scores of all domains of Skindex-16, including symptoms (39.58 vs 8.33, P < .0001), emotions (58.33 vs 15.48, P < .0001), functioning (46.67 vs 13.33, P < .0001) and composite (52.60 vs 14.06, P < .0001).
UNASSIGNED: External application of clearing heat and removing dampness was proven to be an effective and safe treatment for such patients. In the future, high-quality trials are required to determine its clinical application in the field of ircAEs.
UNASSIGNED: A retrospective study of patients with grade 2 to 3 immune-related rash in our hospital from December 2019 to December 2022 was conducted. These patients received QRLSF treatment. Clinical characteristics, treatment outcome, and health-related quality of life (HrQoL) were analyzed.
UNASSIGNED: Thirty patients with grade 2 to 3 rash (median onset time: 64.5 days) were included. The skin lesions of 24 cases (80%) returned to grade 1 with a median time of 8 days. The accompanying symptoms were also improved with median time of 3 to 4 days. The addition of antihistamine (AH) drug didn\'t increase the efficacy of QRLSF (AH + QRLSF: 75.00% vs QRLSF: 83.33%, P = .66). No significant difference was observed in the efficacy of QRLSF treatment regardless of whether patients had previously received CS therapy (untreated population: 88.24% vs treated population: 69.23%, P = .36). During 1-month follow-up, 2 cases (8.33%) underwent relapses. In terms of HrQoL, QRLSF treatment could significantly reduce the median scores of all domains of Skindex-16, including symptoms (39.58 vs 8.33, P < .0001), emotions (58.33 vs 15.48, P < .0001), functioning (46.67 vs 13.33, P < .0001) and composite (52.60 vs 14.06, P < .0001).
UNASSIGNED: External application of clearing heat and removing dampness was proven to be an effective and safe treatment for such patients. In the future, high-quality trials are required to determine its clinical application in the field of ircAEs.
摘要：
■在中国，2~3级免疫相关皮疹可能导致免疫治疗中断.皮质类固醇（CS）是主要的治疗方法，但并不总是有效的。清热祛湿的外部应用，以清-Re-Li-Shi公式(QRLSF)表示，在过去的5年中，我们医院一直用于治疗免疫相关的皮肤不良事件（ircAE）。目的探讨其治疗2～3级皮疹的疗效和安全性。
■对我院2019年12月至2022年12月的2至3级免疫相关性皮疹患者进行了回顾性研究。这些患者接受QRLSF治疗。临床特征,治疗结果,并对健康相关生活质量(HrQoL)进行分析。
■纳入30例2-3级皮疹患者（中位发病时间：64.5天）。24例（80％）的皮肤病变恢复到1级，中位时间为8天。伴随症状也得到改善，中位时间为3至4天。添加抗组胺药(AH)并没有增加QRLSF的疗效(AH+QRLSF:75.00%vsQRLSF:83.33%,P=.66）。无论患者以前是否接受过CS治疗，QRLSF治疗的疗效均无明显差异（未治疗人群：88.24％与治疗人群：69.23％，P=.36）。在1个月的随访中，2例(8.33%)复发。就HrQoL而言，QRLSF治疗可显着降低Skindex-16所有领域的中位数得分，包括症状（39.58vs8.33，P<0.0001），情绪（58.33vs15.48，P<0.0001），功能（46.67vs13.33，P<.0001）和复合（52.60vs14.06，P<.0001）。
■外部应用清热除湿被证明是对此类患者的有效且安全的治疗方法。在未来,需要高质量的试验来确定其在ircAE领域的临床应用。
■对我院2019年12月至2022年12月的2至3级免疫相关性皮疹患者进行了回顾性研究。这些患者接受QRLSF治疗。临床特征,治疗结果,并对健康相关生活质量(HrQoL)进行分析。
■纳入30例2-3级皮疹患者（中位发病时间：64.5天）。24例（80％）的皮肤病变恢复到1级，中位时间为8天。伴随症状也得到改善，中位时间为3至4天。添加抗组胺药(AH)并没有增加QRLSF的疗效(AH+QRLSF:75.00%vsQRLSF:83.33%,P=.66）。无论患者以前是否接受过CS治疗，QRLSF治疗的疗效均无明显差异（未治疗人群：88.24％与治疗人群：69.23％，P=.36）。在1个月的随访中，2例(8.33%)复发。就HrQoL而言，QRLSF治疗可显着降低Skindex-16所有领域的中位数得分，包括症状（39.58vs8.33，P<0.0001），情绪（58.33vs15.48，P<0.0001），功能（46.67vs13.33，P<.0001）和复合（52.60vs14.06，P<.0001）。
■外部应用清热除湿被证明是对此类患者的有效且安全的治疗方法。在未来,需要高质量的试验来确定其在ircAE领域的临床应用。
